Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17β-estradiol

Hypertension

Volumn 56, Issue 3, 2010, Pages 405-411

  Novensa, Laura ^a   Selent, Jana ^b   Pastor, Manuel ^b   Sandberg, Kathryn ^c   Heras, Magda ^a   Dantas, Ana Paula ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

17 estradiol; conjugated equine estrogens; endothelium; eNOS transcription; NO

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; EQUILENIN; EQUILIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; NITRIC OXIDE;

ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE ACTIVATION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

CELLS, CULTURED; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGENS, CONJUGATED (USP); HUMANS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 77955984016     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.151969     Document Type: Article

References (33)

1. Dantas APV, Sandberg K. Challenges and opportunities associated with targeting estrogen receptors in treating hypertension and cardiovascular disease. Drug Discov Today Ther Strateg. 2005;2:245-251.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A Prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
4. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: a prospective, observational study. Ann Intern Med. 2001;135:1-8.
5. Dantas AP, Franco Mdo C, Tostes RC, Fortes ZB, Costa SG, Nigro D, Carvalho MH. Relative contribution of estrogen withdrawal and gonadotropins increase secondary to ovariectomy on prostaglandin generation in mesenteric microvessels. J Cardiovasc Pharmacol. 2004;43:48-55.
6. Dantas AP, Scivoletto R, Fortes ZB, Nigro D, Carvalho MH. Influence of female sex hormones on endothelium-derived vasoconstrictor prostanoid generation in microvessels of spontaneously hypertensive rats. Hypertension. 1999;34:914-919.
7. Dantas AP, Tostes RC, Fortes ZB, Costa SG, Nigro D, Carvalho MH. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension. 2002;39:405-411.
8. Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgrad Med. 2009;121:73-85.
9. Huang A, Sun D, Kaley G, Koller A. Estrogen maintains nitric oxide synthesis in arterioles of female hypertensive rats. Hypertension. 1997; 29:1351-1356.
10. Sumi D, Ignarro LJ. Estrogen-related receptor a 1 up-regulates endothelial nitric oxide synthase expression. Proc Natl Acad Sci USA. 2003;100: 14451-14456.
11. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001;276: 3459-3467.
12. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev. 2002;23:665-686.
13. Murano T, Izumi S, Kika G, Haque SF, Okuwaki S, Mori A, Suzuki T, Matsubayashi H, Ikeda M, Goya K, Makino T. Impact of menopause on lipid and bone metabolism and effect of hormone replacement therapy. Tokai J Exp Clin Med. 2003;28:109-119.
14. Clark KE, Baker RS, Lang U. Premarin-induced increases in coronary and uterine blood flow in nonpregnant sheep. Am J Obstet Gynecol. 2000;183:12-17. (Pubitemid 30626020)
15. Okano HMD, Jayachandran MP, Yoshikawa AMD, Miller VMP. Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. J Cardiovasc Pharmacol. 2006;47:621-628.
16. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54:11-18.
17. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005;66:295-306.
18. Meyer MR, Haas E, Barton M. Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. Gend Med. 2008;5(suppl A):S19-S33.
19. Wingrove CS, GarrE, Pickar JH, Dey M, Stevenson JC. Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells. Mol Cell Endocrinol. 1999;150:33-37.
20. Bhavnani BR, Tam S-P, Lu X. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ER{a } and ER{/3 }. Endocrinology. 2008;149:4857-4870.
21. Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits? Arterioscler Thromb Vasc Biol. 2007;27:1669-1672.
22. Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006; 3:254-269.
23. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
24. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol. 2009;170:12-23.
25. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15:35-44. (Pubitemid 43192860)
26. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab. 2004;15:73-78.
27. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74:279-285.
28. Katzenellenbogen JA, Katzenellenbogen BS. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol. 1996;3:529-536.
29. Kakui K, Itoh H, Sagawa N, Yura S, Korita D, Takemura M, Miyamaoto Y, Saito Y, Nakao K, Fujii S. Augmented endothelial nitric oxide synthase (eNOS) protein expression in human pregnant myometrium: possible involvement of eNOS promoter activation by estrogen via both estrogen receptor (ER)a and ER/3. Mol Hum Reprod. 2004;10:115-122.
30. Georgescu SP, Li JH, Lu Q, Karas RH, Brown M, Mendelsohn ME. Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptom. Mol Endocrinol. 2005;19:2491-2501.
31. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the a-, but not/3-, estrogen receptor. Circ Res. 2002;90:413-419.
32. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, Sheehan DM. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci. 2000;54:138-153.
33. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin. Steroids. 2008;73:59-68.